Study Objective. To identify patient-specific factors associated with spironolactone-induced potassium level elevation in patients with heart failure. Design. Prospective cohort study. Setting. Two adult heart failure clinics. Patients. Sixty-two adult (mean ± SD age 54 ± 16 yrs) aldosterone antagonistnaïve patients with heart failure. Intervention. Patients received spironolactone 12.5 mg/day, titrated to 25 mg/day if tolerated. Measurements and Main Results. Blood samples were obtained at baseline, 1 week after spironolactone initiation, and 1 week after spironolactone dose titration for assessment of baseline aldosterone level, serum chemistry, and angiotensinogen (AGT) c.-6G>A and p.M268T and mineralocorticoid receptor (NR3C2) c.215C>G and p.I180V genotypes. Patient characteristics, laboratory values, and genotypes were compared between those whose potassium levels increased by more than 0.5 mEq/L (15 patients) and those with lower potassium level elevations (47 patients) after spironolactone initiation and dose titration. Patients with a greater potassium level elevation had a higher mean ± SD aldosterone concentration (178 ± 92 vs 102 ± 57 pg/ml, p=0.007) and NR3C2 215G allele frequency (50% vs 22%, p<0.01). Aldosterone concentrations positively correlated with diuretic dose (r=0.313, p=0.014) and negatively correlated with serum potassium level (r=−0.319, p=0.012). On regression analysis, factors predictive of potassium level increases greater than 0.5 mEq/L with spironolactone were aldosterone level greater than 150 pg/ml (odds ratio [OR] 30, 95% confidence interval [CI] 3.2-287] and NR3C2 215G carrier status (OR 17, 95% CI 1.6-167). Conclusion. Our data suggest that potassium should be monitored with particular caution when spironolactone is started in patients with heart failure who have evidence of elevated aldosterone levels, such as high diuretic requirements, or the NR3C2 215G allele.
the renal and cardiac effects of aldosterone by competitively inhibiting aldosterone binding to the mineralocorticoid receptor, also known as the nuclear receptor superfamily 3, group C, member 2 (NR3C2). The Randomized Aldactone Evaluation Study (RALES) showed that the addition of spironolactone to standard therapy in patients with severe heart failure improved overall survival and reduced the risk for heart failurerelated hospitalization. 3 Based on the RALES findings, consideration of spironolactone is recommended for heart failure patients with continued symptoms despite standard therapy. 4 The benefits of spironolactone are partially offset by an increased risk of hyperkalemia. Renal dysfunction, diabetes mellitus, and concomitant treatment with other renin-angiotensin system antagonists increase this risk. [5] [6] [7] [8] In addition, we found that Caucasians had greater potassium level elevations with spironolactone compared with African-Americans. 9, 10 Racial differences in spironolactone response are possibly secondary to racial differences in the distribution of genetic polymorphisms involved in eliciting spironolactone' s effects.
Candidate genes for influencing spironolactone response include the genes for NR3C2, the target site for spironolactone, and angiotensinogen (AGT), a precursor hormone for stimulating aldosterone release. Two single-nucleotide polymorphisms (SNPs) occur in the NR3C2 gene at position -2 (c.215C>G, rs2070951) before the exon 2 start codon and at codon 180 (p.I180V, rs5522) in exon 2. In vitro studies have demonstrated greater luciferase activity with the 215G and 180V alleles. 11 The reported frequency of the 215G allele is approximately 0.45 in Caucasians and 0.20-0.30 in African populations, whereas the reported 180V allele frequency ranges from 0.07-0.13 in both Caucasian and AfricanAmerican populations. 12, 13 Common SNPs in the AGT gene's 5′ -promoter region (c.-6G>A, rs5051) and in exon 2 (p.M268T, rs699) have been correlated with gene transcription, AGT and aldosterone concentrations, and responses to angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers. [14] [15] [16] [17] [18] The -6A and 268T alleles are in strong linkage disequilibrium and occur at frequencies of approximately 0.45 in Caucasians and 0.85 in AfricanAmericans. 19, 20 We hypothesized that the NR3C2 and AGT genotypes, in combination with clinical factors, influence the risk for potassium level elevation with spironolactone in patients with heart failure. The objective of this study was to determine the association between patient-specific factors, including NR3C2 and AGT genotypes, and spironolactone-induced potassium level elevation in patients with heart failure.
Methods

Study Population
Adults were enrolled from the Heart Failure Clinics at the University of Illinois at Chicago Medical Center and the Evanston Northwestern Medical Center (Evanston, IL). Inclusion criteria were the diagnosis of heart failure, evidence of systolic dysfunction and a left ventricular ejection fraction less than 45% by echocardiography within the previous 6 months, and treatment with either an ACE inhibitor or angiotensin II receptor blocker. Patients with a serum potassium concentration of 5.0 mEq/L or greater, serum creatinine concentration of 2.5 mg/dl or greater, treatment with an aldosterone antagonist within the previous 12 months, or treatment with other potassium-sparing diuretics were excluded. Patients followed in the heart failure clinics are routinely counseled on limiting dietary sodium to less than 2 g/day. No additional dietary modifications were required for the study. The study was performed in accordance with the Declaration of Helsinki and approved by the institutional review board at each location.
Study Procedures and Data Collection
Once the clinical decision was made to start spironolactone and written informed consent and authorization for medical record review were obtained, a 20-ml venous blood sample was collected in serum separator tubes for determination of serum potassium, creatinine, and aldosterone concentrations, and a 5-ml sample was collected in an ethylenediaminetetraacetic acid-containing tube for genotyping. All blood samples were drawn between 8:00 A.M. and 12:00 P.M. while patients were seated after being upright for 2 or more hours. Although aldosterone exhibits diurnal variation, with the lowest concentration around midnight and peak levels in the early morning hours, the variation between 8:00 A.M. and 12:00 P.M. is minimal. 21, 22 Spironolactone was started at a dose of 12.5 mg/day. Patients were asked to return 1 week after spironolactone initiation for reassessment of blood chemistry. If potassium and creatinine levels remained below 5.0 mEq/L and 2.5 mg/dl, respectively, the spironolactone dose was increased to 25 mg/day. Patients were asked to return 1 week after spironolactone dose titration for reassessment of blood chemistry. Changes in potassium supplementation and other drugs were made at the discretion of the treating clinician. Spironolactone tablets were provided by members of the research team. Demographic and clinical data were collected through patient interview, physical examination, and review of the medical record.
Laboratory Analyses
Serum was stored at −70ºC until analysis. Aldosterone concentrations were determined in duplicate by radioimmunoassay with a commercially available kit (Diagnostic Systems Laboratories, Inc., Webster, TX). Intraassay and interassay coefficients of variation with this assay in our laboratory were 1.5% and 1.9%, respectively. Serum chemistry was determined in the clinical laboratory at each institution.
Genotyping
Whole blood was stored at −20ºC until genomic DNA isolation by using a commercially available kit (PureGene; Qiagen, Valencia, CA). Genotypes were determined by polymerase chain reaction and pyrosequencing (for NR3C2 SNPs) or bidirectional capillary sequencing (for AGT SNPs). Pyrosequencing was done with a PSQ HS96 Pyrosequencer (Biotage, Charlottesville, VA) and PSQ96 SNP software, version 1.2.1. Capillary sequencing was performed by using an ABI PRISM 3100 Genetic Analyzer and BigDye TerminatorR technology, version 3.1 (Applied Biosystems, Foster City, CA). Each polymerase chain reaction consisted of 25 µl of HotStarTaq Master Mix (Qiagen), 25 pmol of each primer (Table 1) , and 20-100 ng of DNA. Amplification consisted of denaturation at 95°C for 15 minutes, then 38-45 cycles of denaturation at 94°C for 30 seconds, annealing for 30 seconds (at 57°C for NR3C2 c.215C>G, 60°C for NR3C2 p.I180V and AGT p.M268T, and 61°C for AGT -6G>A), and extension at 72°C for 1 minute, with a final extension of 72°C for 10 minutes. To verify the specificity of the genotyping reactions, 20% of NR3C2 genotypes were confirmed by capillary sequencing. All genotypes were scored by two independent investigators masked to potassium results.
Statistical Analysis
Creatinine clearance was calculated by using the equation of Cockcroft and Gault and ideal body weight. 23 The linkage disequilibrium measure D′ was calculated for the AGT polymorphism loci with SNPAnalyzer (http://snp. istech.info/istech/board/1.2A/), using the expectation-maximization algorithm. 24 Characteristics and genotype distributions were compared between patients whose potassium levels increased by 0.50 mEq/L or less (lowresponse group) or by more than 0.50 mEq/L (high-response group) with spironolactone by using 2 analysis or the Fisher exact test where appropriate for nominal data and the Student unpaired t test or Mann Whitney U test as appropriate for continuous data. Changes in concomitant drug doses during spironolactone dose titration were analyzed within each group the inclusion of at least 60 total patients provided at least 80% power to detect a 40% difference in genotype distribution between potassium response groups.
Results
Patient Characteristics
Of 68 patients approached about the study between November 2001 and November 2007, 62 patients (45 African-Americans and 17 Caucasians) provided written informed consent for study participation. The mean ± SD age of study patients was 54 ± 16 years, and 40% were female. Most patients (65%) had New York Heart Association functional class 3 heart failure, with a mean ± SD ejection fraction of 23 ± 11%. Most patients had a nonischemic etiology for their heart failure (61%) and had relatively preserved renal function (median creatinine clearance 60 ml/min, interquartile range 46-77 ml/min). Patients were well treated with respect to vasodilator and ␤-blocker therapy; all were receiving an ACE inhibitor and/or angiotensin II receptor blocker (according to inclusion criteria), and 97% were taking a ␤-blocker. Doses of vasodilators, ␤-blockers, diuretics, and potassium were stable for 4 or more weeks before start of spironolactone therapy for 88% of patients and for 2 or more weeks for all patients.
Genotype Distribution Allele and genotype frequencies are shown in Table 2 . No patient was homozygous for the NR3C2 180V allele. Frequencies of the NR3C2 215G, AGT -6G, and AGT 268M alleles were higher in Caucasians compared with AfricanAmericans, as previously reported. 12, 19, 20 The AGT SNPs were in strong linkage disequilibrium (D′=0.9541) and primarily formed the -6A/268T and -6G/268M diplotypes.
Response to Spironolactone
With spironolactone initiation and dose titration, median increases in serum creatinine and potassium concentrations among the study population were 0.10 mg/dl and 0.20 mEq/L, respectively. There was substantial interpatient variability in potassium response, with potassium changes ranging from −0.80-1.8 mEq/L. Serum potassium level increased by more than 0.5 Baseline characteristics at the time of spironolactone initiation in patients who subsequently had low (≤ 0.5 mEq/L) or high (> 0.5 mEq/L) potassium responses to spironolactone are shown in Table 3 . Spironolactone dose was titrated to a mean ± SD of 22 ± 6 and 21 ± 6 mg/day in the low-and high-response groups, respectively (p=0.70). There were no significant changes in potassium supplementation, diuretic therapy, or other concomitant therapy in either group during spironolactone initiation and dose titration.
Nongenetic factors potentially associated (p<0.10) with greater potassium response by univariate analysis were Caucasian race, ischemic heart disease, absence of ␤-blocker therapy, potassium supplement use, higher diuretic and potassium doses, low baseline potassium level, decreased renal function, and increased aldosterone level (Table 3) . Ischemic heart disease correlated with race (p=0.010). Aldosterone was inversely correlated with serum potassium level (r=−0.319, p=0.012) and ␤-blocker treatment (p=0.003) and directly correlated with diuretic dose (r=0.313, p=0.014), potassium supplement use (p<0.01), and potassium supplement dose (r=0.462, p=0.008).
Genetic Associations with Potassium Response
As shown in Figure 1 , distribution of the NR3C2 I180V and AGT genotypes was similar in the high-and low-potassium response groups. However, significantly more patients in the highresponse group carried an NR3C2 215G allele (67% vs 32%, p=0.017). The NR3C2 215G allele frequency was 50% in the high-response group and 22% in the low-response group (p<0.01).
Multivariate Analysis of Factors Associated with Potassium Response
The multivariate analysis including the factors shown in Table 4 showed that an aldosterone level greater than 150 pg/ml and the NR3C2 215G allele were significantly associated with greater potassium response to spironolactone. Creatinine clearance below the first quartile for the study population (< 46 ml/min) tended to be associated with greater potassium response. With the posterior inclusion of ischemic heart disease, ␤-blocker use, serum potassium level, and diuretic dose into the multivariate analysis, aldosterone concentration and NR3C2 genotype remained associated with potassium response (analysis not shown).
Discussion
The rate of serious hyperkalemia was only 2% in RALES. 3 However, data from clinical practice suggest that spironolactone-induced hyperkalemia is much more common outside the controlled clinical trial setting. 6, 25, 26 Current guidelines outline strategies for minimizing the risk of hyperkalemia, and chief among these is the recommendation to avoid spironolactone in patients with an increased serum creatinine concentration (≥ 2.5 mEq/L in men and ≥ 2.0 mEq/L in women). 4 However, spironolactone may cause significant potassium level elevation in the absence of renal dysfunction. For example, 40% of patients in our study with a potassium increase of more than 0.50 mEq/L had an estimated creatinine clearance greater than 60 ml/minute.
In our study, both circulating aldosterone and NR3C2 215C>G genotype were significantly associated with potassium level elevations with spironolactone. Spironolactone exerts its effects by competitively inhibiting aldosterone binding to the NR3C2, and thus, it is not surprising that patients with higher aldosterone concentrations Low-potassium response group High-potassium response group might experience greater effects from aldosterone antagonism. However, it is not necessarily intuitive to expect a patient receiving a high dose of a diuretic and needing potassium supplementation to be at risk for significant potassium level elevation with aldosterone antagonism. Yet, higher diuretic doses and potassium supplement use correlated with higher aldosterone concentrations in our study. These correlations likely reflect greater sodium reabsorption and potassium excretion in the presence of elevated aldosterone. The NR3C2 215C>G polymorphism is located in the sequence that surrounds the translation initiation site of exon 2, often referred to as the Kozak sequence, a region shown to alter the efficiency of messenger RNA translation and the quantity of final protein produced. [27] [28] [29] There are limited data on the clinical consequences of NR3C2 variations, with most studies focusing on NR3C2 variants underlying pseudohypoaldosteronism, monogenic hypertension, or hypertension phenotypes in the general population. 30, 31 Our finding of greater potassium response to spironolactone with the NR3C2 215G allele is consistent with the in vitro data showing that this allele has greater functional effects. 11 The frequency of the NR3C2 215G allele, associated with greater potassium increases, was higher in Caucasians than African-Americans and potentially explains our previously observed racial differences in potassium response to spironolactone. 9, 10 In support of this, with the inclusion of both race and NR3C2 genotype in our regression model, race was no longer associated with spironolactone-induced potassium level elevation.
Similar to previous studies, renal function tended to be associated with greater spironolactone-induced potassium level increases. [6] [7] [8] 26 Patients in our study were generally younger and had better renal function than those in previous studies linking renal dysfunction to risk for hyperkalemia with spironolactone. Results from our regression analysis suggest that in a patient population with characteristics similar to ours (i.e., median age of 55 yrs with largely preserved renal function), aldosterone concentrations and genotype are more important predictors of risk for serious potassium level elevations with spironolactone than is renal function.
Only one patient in our study had a serum potassium level greater than 5.5 mEq/L with spironolactone, and none developed serious hyperkalemia. The low frequency of hyperkalemia may be attributable to our practice of starting spironolactone at a dose of 12.5 mg/day, with uptitration if tolerated. Nonetheless, over 20% of the study patients had a clinically significant potassium level increase (> 0.5 mEq/L) despite this conservative approach to dosing, and nearly 10% had a potassium level increase greater than 0.5 mEq/L with the 12.5-mg/day dosage. The large percentage of African-Americans in our population, in whom we have previously reported lower spironolactone-induced potassium level elevations, may also have contributed to the low frequency of hyperkalemia. 9 Indeed, based on our observations of minimal potassium level increases among African-Americans, clinicians in our heart failure clinics have a fairly high threshold for stopping potassium supplements when starting low-dose spironolactone in our AfricanAmerican patients, as apparent in our study.
Another limitation of our study is that we did not control dietary sodium intake before aldosterone measurement and thus cannot account for interday variability in aldosterone levels due to varying sodium intake. However, all patients in our clinics are routinely counseled about sodium restriction, possibly limiting the effects of dietary sodium on aldosterone. A third limitation is that an increased sample size might have enhanced the ability to reliably estimate a higher dimension regression model, including additional genotypes, associated with spironolactone response. Given that the sample size calculation was based solely on detecting genetic differences, the present regression model may, in addition, provide data to better inform sample size calculations for further studies of determinants of aldosterone antagonist response. Although serum potassium level remained within an acceptable range for most of our patients, we believe that our findings still have important implications. First, our study supports starting spironolactone at a dose of 12.5 mg/day, as discussed above. Second, our data suggest that potassium should be carefully monitored in individuals with evidence of elevated aldosterone levels, such as those requiring high doses of loop diuretics. Third, our findings suggest that NR3C2 genotype may be useful in predicting potassium response to spironolactone. Furthermore, given that both the renal effects (potassium secretion) and cardiac effects (ventricular remodeling) of spironolactone are mediated through NR3C2 blockade, it is possible that NR3C2 genotype also influences cardiac response to the drug. 32 There are limited data on genetic determinants of cardiac response to aldosterone antagonists, and the effect of NR3C2 genotype on cardiac response has yet to be determined.
Conclusion
We found higher aldosterone concentrations and a higher frequency of the NR3C2 215G allele among patients with greater potassium level elevations with spironolactone therapy for heart failure. Our data suggest that aldosterone concentration and NR3C2 genotype are predictive of potassium response to aldosterone antagonists. However, our findings require confirmation, particularly given our limited sample size. Ultimately, if our findings are confirmed, insight into the patient-specific factors that influence spironolactone response could lead to the ability to predict which patients are at the greatest risk for serious potassium level elevations with aldosterone antagonists and to tailor therapy accordingly. Specifically, spironolactone could be started at lower doses with slower dose titration and closer electrolyte monitoring in patients at high risk for potassium level elevations based on their genotype and/or clinical characteristics. Clinicians could also be more diligent about reducing or discontinuing potassium supplements in high-risk patients, regardless of baseline potassium level. Alternatively, information about factors associated with serious potassium level elevations with spironolactone could lead to improved use of the drug in patients at low risk for hyperkalemia.
